Investor Presentaiton slide image

Investor Presentaiton

Our business has significant opportunities beyond external expectations Strong Foundation • R&D has delivered: 9 new medicines, numerous milestones • Commercial execution is strong: Key Inline & New Products continue to grow Business momentum is robust: Strong base business & expanding New Product Portfolio 2023-2030 BMY External vs Internal Revenue Drivers Consensus Drivers Drivers of Internal Conviction ⚫ IRA • LOE Exposure In-line and recently launched products with significant commercial opportunities • 12 rapidly advancing new medicines in or near registrational development R&D productivity and efficiency enhancements Strong financial capacity for business development Bristol Myers Squibb™ Not for Product Promotional Use 5 LO
View entire presentation